Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Clinical trial NCT03924856 · COMPLETED
Trial details
- NCT number
- NCT03924856
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-13
- Primary completion
- 2026-01-26
- Enrollment
- 907
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.